[Executive functions disorders in children with dyslexia].

Chutko LS, Surushkina SY, Yakovenko EA, I Anisimova T, Didur MD, Chekalova SA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2021Cited by 4 (Europe PMC)

PMID33728849DOI10.17116/jnevro202112102138PepBankPUB-33728849

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

2 results from studies that gave the peptide. 2 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with dyslexia, improvement was slightly more frequent with Cortexin than encephabol.
In plain wordsChildren with dyslexia improved slightly more often with Cortexin than encephabol.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseTreatment improvement proportion
Study
n = 60
Comparator
Encephabol
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Improvement
73.3%
Cortexin
Improvement
60%
encephabol
Source sentences
Summary
However, the effectiveness of treatment with cortexin was slightly higher compared to encephabol (improvement was noted in 73.3% and 60.0%of patients, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
Cortexin was used to treat 30 patients from the study group, 30 patients received encephabol.
Summary · context
A control study to analyze the effectiveness of the therapy was carried out one month after the end of therapy.
Report a problemFND-3372884904
02HumanNon-randomized trialMechanism
In children with dyslexia, EEG changes after Cortexin treatment indicated activation of brain regulatory systems.
In plain wordsChildren with dyslexia showed EEG changes after Cortexin treatment that indicated more active brain regulatory systems.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseEEG regulatory activation
Study
n = 30
Outcome group
Receptor activity and mechanism · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
According to a comparative analysis of EEG results, after a course of treatment with cortexin, children with dyslexia have significant neurophysiological changes that indicate the activation of the brain regulatory systems.
2 context sentences(design, population, supporting numbers)
Summary · context
Cortexin was used to treat 30 patients from the study group, 30 patients received encephabol.
Summary · context
A control study to analyze the effectiveness of the therapy was carried out one month after the end of therapy.
Report a problemFND-3372884905

Studies that did not test the peptide alone3

In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cortexin (cortical polypeptide complex).

03HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome
In children with dyslexia, reading skills increased significantly in both the Cortexin and encephabol groups after treatment.
In plain wordsChildren with dyslexia showed significantly better reading skills after treatment in both the Cortexin and encephabol groups.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseReading skills
Study
n = 60
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
The results of the control study after treatment showed a significant increase in reading skills in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Cortexin was used to treat 30 patients from the study group, 30 patients received encephabol.
Summary · context
A control study to analyze the effectiveness of the therapy was carried out one month after the end of therapy.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3372884901
04HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome
In children with dyslexia, attention improved after treatment in the Cortexin and encephabol study.
In plain wordsChildren with dyslexia showed better attention after treatment in the Cortexin and encephabol study.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseAttention
Study
n = 60
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
In addition, there was an improvement in indicators of attention and working memory.
2 context sentences(design, population, supporting numbers)
Summary · context
Cortexin was used to treat 30 patients from the study group, 30 patients received encephabol.
Summary · context
A control study to analyze the effectiveness of the therapy was carried out one month after the end of therapy.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3372884902
05HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome
In children with dyslexia, working memory improved after treatment in the Cortexin and encephabol study.
In plain wordsChildren with dyslexia showed better working memory after treatment in the Cortexin and encephabol study.
Peptide
Cortexin (cortical polypeptide complex)
Outcome
IncreaseWorking memory
Study
n = 60
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
In addition, there was an improvement in indicators of attention and working memory.
2 context sentences(design, population, supporting numbers)
Summary · context
Cortexin was used to treat 30 patients from the study group, 30 patients received encephabol.
Summary · context
A control study to analyze the effectiveness of the therapy was carried out one month after the end of therapy.
In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).
Report a problemFND-3372884903

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.